Protocol
13-112
Full Title
A Single Arm Study of SNX-5422 in Subjects with Selected HER2 Positive Cancers
Purpose
HER2 is a protein that fuels cancer growth and is active in several types of cancer. SNX-5422 is an investigational drug designed to fight cancer by inhibiting HER2. SNX-5422 is taken orally (by mouth).
The purpose of this study is to evaluate the safety and effectiveness of SNX-5422 in patients with HER2-positive cancers of the breast, esophagus, stomach, lung (non-small cell), bladder, or other urothelial cancers that have spread despite other treatments.
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have HER2-positive cancers of the breast, esophagus, stomach, lung (non-small cell), bladder, or other urothelial cancers that have spread despite other treatments.
- Patients should have had at least one but no more than five prior regimens of therapy.
- Patients with breast and esophagogastric cancers must have experienced continued cancer growth despite prior treatment with trastuzumab.
- At least 4 weeks must have passed since completion of prior therapies and entry into the study.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Martin Voss at 646-422-4631.
Disease(s)
Bladder Cancer
Breast Cancer
Kidney Cancer
Lung Cancer, Non-Small Cell
Upper Gastrointestinal: Esophageal Cancer
Upper Gastrointestinal: Gastric Cancer
Locations
